• Something wrong with this record ?

Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry

P. Vynckier, G. Ferrannini, L. Rydén, L. Tokgözoğlu, J. Bruthans, K. Kotseva, D. Wood, T. De Backer, S. Gevaert, D. De Bacquer, D. De Smedt, EUROASPIRE V Investigators group

. 2021 ; 35 (4) : 801-808. [pub] 20201017

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22003981
E-resources Online Full text

NLK ProQuest Central from 1999-03-01 to 1 year ago
Medline Complete (EBSCOhost) from 2011-02-01 to 1 year ago
Health & Medicine (ProQuest) from 1999-03-01 to 1 year ago

Links

PubMed 33068226
DOI 10.1007/s10557-020-07095-6
Knihovny.cz E-resources

PURPOSE: This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). METHODS: Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (≥ 6 months to < 2 years after hospitalization) was collected. RESULTS: Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%; P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%; P < 0.001) and calcium channel blockers (21.2% vs. 28.8%; P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%; P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%; P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. CONCLUSION: The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003981
003      
CZ-PrNML
005      
20220127145651.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10557-020-07095-6 $2 doi
035    __
$a (PubMed)33068226
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vynckier, Pieter $u Department of Public Health and Primary Care, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium. Pieter.Vynckier@Ugent.be
245    10
$a Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry / $c P. Vynckier, G. Ferrannini, L. Rydén, L. Tokgözoğlu, J. Bruthans, K. Kotseva, D. Wood, T. De Backer, S. Gevaert, D. De Bacquer, D. De Smedt, EUROASPIRE V Investigators group
520    9_
$a PURPOSE: This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). METHODS: Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (≥ 6 months to < 2 years after hospitalization) was collected. RESULTS: Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%; P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%; P < 0.001) and calcium channel blockers (21.2% vs. 28.8%; P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%; P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%; P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. CONCLUSION: The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.
650    _2
$a kardiovaskulární rehabilitace $x statistika a číselné údaje $7 D000072038
650    12
$a kardiovaskulární látky $x klasifikace $x terapeutické užití $7 D002317
650    _2
$a koronární bypass $x statistika a číselné údaje $7 D001026
650    12
$a koronární nemoc $x farmakoterapie $x epidemiologie $x prevence a kontrola $7 D003327
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdraví - znalosti, postoje, praxe $7 D007722
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a management péče o pacienta $x metody $x statistika a číselné údaje $7 D010346
650    _2
$a lékařská praxe - způsoby provádění $7 D010818
650    _2
$a sekundární prevence $x metody $7 D055502
650    _2
$a sexuální faktory $7 D012737
650    _2
$a zdraví žen $7 D016387
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ferrannini, Giulia $u Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Rydén, Lars $u Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Tokgözoğlu, Lale $u Department of Cardiology, Hacettepe University, Ankara, Turkey
700    1_
$a Bruthans, Jan $u Centre for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University, Prague, Czech Republic
700    1_
$a Kotseva, Kornelia $u National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Ireland $u National Heart & Lung Institute Imperial College London, London, UK
700    1_
$a Wood, David $u National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Ireland $u National Heart & Lung Institute Imperial College London, London, UK
700    1_
$a De Backer, Tine $u Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium
700    1_
$a Gevaert, Sofie $u Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium
700    1_
$a De Bacquer, Dirk $u Department of Public Health and Primary Care, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium
700    1_
$a De Smedt, Delphine $u Department of Public Health and Primary Care, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium
710    2_
$a EUROASPIRE V Investigators group
773    0_
$w MED00001057 $t Cardiovascular drugs and therapy $x 1573-7241 $g Roč. 35, č. 4 (2021), s. 801-808
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33068226 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145647 $b ABA008
999    __
$a ok $b bmc $g 1751441 $s 1155130
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 4 $d 801-808 $e 20201017 $i 1573-7241 $m Cardiovascular drugs and therapy $n Cardiovasc Drugs Ther $x MED00001057
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options